The VIVITROL® (naltrexone for extended-release injectable suspension) Co-pay Savings Program covers up to $500/month of VIVITROL co-pay or deductible expenses for eligible patients.
1. Data derived from insured patients enrolled in the VIVITROL® Co-pay Savings Program from March 2014 through February 2015.
*Eligibility for Alkermes-Sponsored VIVITROL® Co-pay Assistance:
Offer valid only for prescriptions for FDA-approved indications. You must be at least 18 years old. If you are purchasing your Vivitrol prescriptions with benefits from Medicare, including Medicare Part D or Medicare Advantage plans; Medicaid, including Medicaid Managed Care or Alternative Benefit Plans (“ABPs”) under the Affordable Care Act; Medigap; Veterans Administration (“VA”); Department of Defense (“DoD”); TriCare®; or any similar state funded programs such as medical or pharmaceutical assistance programs, you are not eligible for this offer. Void where prohibited by law, taxed or restricted. Alkermes, Inc. reserves the right to rescind, revoke or amend these offers without notice.
You do not meet the eligibility criteria for the VIVITROL® (naltrexone for extended-release injectable suspension) Co-pay Savings Program.
Any patient with a prescription for VIVITROL for alcohol or opioid dependence who is 18 years or older can apply for the VIVITROL® Co-pay Savings Program card. Eligible participants include:
Patients using federal or state healthcare programs to purchase their VIVITROL prescription. View listCollapse list
VIVITROL is a prescription injectable medicine used to:
VIVITROL must be used with other alcohol or drug recovery programs such as counseling.
VIVITROL may not work for everyone and has not been studied in children.
See the Medication Guide for more information about opioid withdrawal and the ingredients in VIVITROL and the liquid used to mix it.
Using opioids, even in amounts that you used before VIVITROL treatment, can lead to accidental overdose, serious injury, coma, or death. To avoid accidental overdose:
Get emergency medical help right away if you have trouble breathing; become very drowsy with slowed breathing; have slow, shallow breathing; feel faint, dizzy, confused; or have other unusual symptoms.
VIVITROL may cause severe injection site reactions, including tissue death. Some injection site reactions have required surgery. Call your doctor right away if you notice any of the following at your injection site:
Tell your doctor about any injection site reaction that concerns you, gets worse over time or does not get better by two weeks after the injection.
To avoid sudden opioid withdrawal, you must stop taking any opioids or opioid-containing medications, including buprenorphine or methadone, for at least 7 to 14 days before starting VIVITROL. If your doctor decides that you don’t need to complete detox first, he or she may give you VIVITROL in a medical facility that can treat sudden opioid withdrawal.
Sudden opioid withdrawal can be severe and may require hospitalization.
Naltrexone, the active ingredient in VIVITROL, can cause liver damage or hepatitis. Tell your doctor if you have any of the following symptoms of liver problems during VIVITROL treatment:
VIVITROL can cause other serious side effects, such as:
Common side effects of VIVITROL include nausea, tiredness, headache, dizziness, vomiting, decreased appetite, painful joints, and muscle cramps; in addition, common side effects in people taking VIVITROL for opioid dependence also include cold symptoms, trouble sleeping, and toothache.
These are not all of the side effects of VIVITROL. For more information, ask your healthcare provider. Tell your doctor right away if you have any side effect that does not go away. See the Medication Guide for more information.
Call your doctor for medical advice about any side effects. You are encouraged to report negative side effects to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.
See the Medication Guide.